New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.
First-in-human study initiations feature variations on well-trodden targets, plus a minor hiccup for OncoC4.
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
After numerous IL-2 failures there are glimmers of hope for the group’s contender, MDNA11.
The company's comparison of its ADCs to Enhertu seems farfetched.